PNC Financial Services Group
IKT icon

PNC Financial Services Group’s Inhibikase Therapeutics IKT Stock Holding History

PNC Financial Services Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$136 Sell
81
-20
-20% -$36 ﹤0.01% 5076
2025
Q4 		$207 Buy
101
+11
+12% +$18 ﹤0.01% 4975
2025
Q3 		$146 Buy
+90
New +$156 ﹤0.01% 4967

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group's IKT Position: Q1 2026 in Review

PNC Financial Services Group reduced its Inhibikase Therapeutics (IKT) stake by 20% in Q1 2026, selling an estimated $36 and leaving 81 shares worth $136. The position accounts for ﹤0.01% of the portfolio, ranked #5076.

PNC Financial Services Group first reported a position in IKT in Q3 2025 and has held it in 3 quarters since. The position peaked at $207 in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • PNC Financial Services Group held 81 shares of Inhibikase Therapeutics worth $136 as of Q1 2026.
  • PNC Financial Services Group sold 20 Inhibikase Therapeutics shares in Q1 2026, an estimated $36.
  • Inhibikase Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #5076 holding.
  • PNC Financial Services Group first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • PNC Financial Services Group's Inhibikase Therapeutics position peaked at $207 in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.